Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer., PMID:40469300
Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer., PMID:40469300
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial., PMID:40425844
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial., PMID:40425844
Advanced Precision Dual Photothermal and Photodynamic Therapy for Prostate Cancer Using PSMA-ICG-Conjugated Gold Nanorods., PMID:40340375
Advanced Precision Dual Photothermal and Photodynamic Therapy for Prostate Cancer Using PSMA-ICG-Conjugated Gold Nanorods., PMID:40340375
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future., PMID:40266437
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future., PMID:40266437
Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer., PMID:40214467
Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer., PMID:40214467
Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model., PMID:40098725
Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model., PMID:40098725
Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen., PMID:40096254
Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen., PMID:40096254
E-Urea-K-Based PSMA Imaging Served as an Alternative in Assessing Tumor Neovascularization via Targeting CD31., PMID:40013667
E-Urea-K-Based PSMA Imaging Served as an Alternative in Assessing Tumor Neovascularization via Targeting CD31., PMID:40013667
Mechanisms of Response and Resistance to PSMA×CD3 Bispecifics in CD34+ Humanized Mice., PMID:40008870
Mechanisms of Response and Resistance to PSMA×CD3 Bispecifics in CD34+ Humanized Mice., PMID:40008870
Optical and MRI-Guided Theranostic Application of Ultrasmall Superparamagnetic Iron Oxide Nanodrug Conjugate for PSMA-Positive Prostate Cancer Therapy., PMID:39933703
Optical and MRI-Guided Theranostic Application of Ultrasmall Superparamagnetic Iron Oxide Nanodrug Conjugate for PSMA-Positive Prostate Cancer Therapy., PMID:39933703
PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny., PMID:39904797
PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny., PMID:39904797
PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging., PMID:39690809
PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging., PMID:39690809
Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors., PMID:39551117
Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors., PMID:39551117
Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy., PMID:39461061
Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy., PMID:39461061
Cellular Membrane-Derived Nanovesicles Expressing hCD64 for Targeting Prostate Cancer., PMID:39316382
Cellular Membrane-Derived Nanovesicles Expressing hCD64 for Targeting Prostate Cancer., PMID:39316382
Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future., PMID:39270526
Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future., PMID:39270526
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer., PMID:39269656
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer., PMID:39269656
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer., PMID:39172730
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer., PMID:39172730
Co-delivery of Siape1 and Melatonin by 125I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer., PMID:39044710
Co-delivery of Siape1 and Melatonin by 125I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer., PMID:39044710
Genetically Engineered Membrane-Coated Nanoparticles for Enhanced Prostate-Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration-Resistant Prostate Cancer., PMID:38946578
Genetically Engineered Membrane-Coated Nanoparticles for Enhanced Prostate-Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration-Resistant Prostate Cancer., PMID:38946578
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?, PMID:38855174
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?, PMID:38855174
Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation., PMID:38832336
Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation., PMID:38832336
Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen., PMID:38821609
Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen., PMID:38821609
Increased α2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high grade group prostate cancer., PMID:38734979
Increased α2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high grade group prostate cancer., PMID:38734979
PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics., PMID:38703588
PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics., PMID:38703588
Discovery of PSMA in the prostate of the common marmoset (Callithrix jacchus)., PMID:38678435
Discovery of PSMA in the prostate of the common marmoset (Callithrix jacchus)., PMID:38678435
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer., PMID:38593212
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer., PMID:38593212
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes., PMID:38446353
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes., PMID:38446353
The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer., PMID:38364991
The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer., PMID:38364991
PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers., PMID:38052377
PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers., PMID:38052377
Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles With PSMA-11 Peptides: A Preclinical Study., PMID:37572082
Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles With PSMA-11 Peptides: A Preclinical Study., PMID:37572082
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer., PMID:36821396
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer., PMID:36821396
Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas., PMID:36728839
Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas., PMID:36728839
Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy., PMID:36476583
Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy., PMID:36476583
[Prokaryotic expression of prostate-specific membrane antigen (PSMA) nanoantibody gene and screening of natural phage nanoantibody library]., PMID:36328433
[Prokaryotic expression of prostate-specific membrane antigen (PSMA) nanoantibody gene and screening of natural phage nanoantibody library]., PMID:36328433
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer., PMID:35849143
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer., PMID:35849143
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease., PMID:35604681
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease., PMID:35604681
Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors., PMID:35467350
Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors., PMID:35467350
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells., PMID:35064078
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells., PMID:35064078
Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer., PMID:34985786
Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer., PMID:34985786
Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity., PMID:34770976
Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity., PMID:34770976
Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells., PMID:34699177
Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells., PMID:34699177
Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy., PMID:34571072
Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy., PMID:34571072
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma., PMID:34541577
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma., PMID:34541577
Ultrasensitive and Selective Impedimetric Determination of Prostate Specific Membrane Antigen Based on Di-Succinimide Functionalized Polythiophene Covered Cost-Effective Indium Tin Oxide., PMID:34263542
Ultrasensitive and Selective Impedimetric Determination of Prostate Specific Membrane Antigen Based on Di-Succinimide Functionalized Polythiophene Covered Cost-Effective Indium Tin Oxide., PMID:34263542
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications., PMID:34167925
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications., PMID:34167925
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release., PMID:34088740
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release., PMID:34088740
Potential and challenges of specifically isolating extracellular vesicles from heterogeneous populations., PMID:34079007
Potential and challenges of specifically isolating extracellular vesicles from heterogeneous populations., PMID:34079007
A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy., PMID:34071152
A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy., PMID:34071152
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models., PMID:34035067
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models., PMID:34035067
For research use only. Not for human or drug use.
